TRANSFORM DEVELOPING IN VITRO CELL CONTROL METHODOLOGY.
TransForm Pharmaceuticals Inc., Lexington, Mass., has received a
contract from the US Defense Advanced Research Projects Agency (DARPA)
to develop a prototype system for the discovery of methods . . .
NEWNEURAL CSO GETS NIH GRANT OF $1.4 MILLION.
NewNeural, Inc., Naperville, Ill., an emerging biotech company
focusing on adult stem cell therapy products, has announced that its
founder and chief scientific officer, Kiminobu Sugaya, PhD, has . . .
RNAI TECHNOLOGY PROMISES TO ACCELERATE DRUG DISCOVERY.
Agilent Technologies Inc. (NYSE: A) and Dharmacon Inc. have formed
a research collaboration to use Agilent's microarray and
Dharmacon's RNA interference (RNAi) technologies to measure the
broader . . .
STUDY INDICATES THEAFLAVIN EXTRACT LOWERS LDL BY 16.4%.
Results of a clinical study documents the effectiveness of a
theaflavin-enriched tea extract to lower LDL cholesterol (LDL- C) by
16.4 percent, with no adverse effects. The all natural, . . .
LIGOCYTE LICENSES KEY PATENT FROM CENTER FOR BLOOD
RESEARCH.
LigoCyte Pharmaceuticals, Inc., Bozeman, Mont., has exclusively
licensed inflammation assay technology from the Center for Blood
Research, an affiliate of Harvard Medical School. Formerly . . .
SERACARE OFFERS BIOBANK DIABETES COLLECTION.
SeraCare Life Sciences (Nasdaq: SRLS), Oceanside, Calif., is
offering the SeraCare BioBank Type 2 Diabetes collection. BioBank is a
proprietary repository of blood products and medical data to . . .
VDDI PHARMACEUTICALS ACQUIRES MEDICAL PEPTIDE PORTFOLIO.
VDDI Pharmaceuticals, a biopharmaceutical development company, has
acquired a portfolio of patents and patent applications from Interlink
Biotechnologies LLC (ILB) that will enable the successful . . .
STUDY SHOWS SECRETIN REDUCES POST-ERCP PANCREATITIS.
Repligen Corporation (NASDAQ:RGEN), Waltham, Mass, has reported
that researchers from Duke University Medical Center have presented
results from a clinical trial that demonstrated that . . .
GENETRONICS/GENTERIC TO DELIVER DNA TO SALIVARY GLAND.
Genetronics Biomedical Corporation (AMEX:GEB) and Genteric, Inc., a
privately held gene therapy company, have signed an exclusive agreement
covering joint evaluation of gene expression . . .
OCTOPLUS/CYTIMMUNE TO DEVELOP SOLID CANCER TREATMENT.
OctoPlus (Leiden, The Netherlands) and CytImmune Sciences, Inc.,
(College Park, USA) have entered into a collaboration agreement to
develop a novel treatment for solid cancers. The treatment's . . .
NIH AWARDS HIV GRANT TO ANTIGEN EXPRESS FOR DNA VACCINE.
Antigen Express, Worcester, Mass. has been awarded a $357,000 NIH
Small Business Innovative Research (SBIR) award that supports
pre-clinical testing of a novel HIV DNA vaccine incorporating . . .
AGILENT DEBUTS FIRST MICROARRAY FOR RICE BLAST DISEASE.
Agilent Technologies, Palo Alto, Calif., has introduced the first
microarray for the study of rice blast disease and rice, the Magnaporthe
grisea Oligo Microarray Kit (G4137A). The new Magnaporthe . . .
SUPERGEN GETS U.S. PATENT FOR IMPROVED PACLITAXEL.
SuperGen Inc. (NASDAQ: SUPG), Dublin, Calif., has been issued U.S.
Patent No. 6,538,020, which covers new and improved formulations of the
anticancer drug paclitaxel, methods of manufacturing these . . .
CURIS GETS PATENT FOR COMPOUND FOR BASEL CELL CARCINOMA.
The U.S. Patent Office has issued Patent 6,552,016 to Curis Inc.,
Cambridge, Mass., covering pharmaceutical preparations containing small
molecule compounds that selectively inhibit a biological . . .
MAXIM FILES U.S. PATENT APPLICATIONS FOR TWO CANCER
TARGETS.
Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM)(SSE:MAXM), San Diego, has
filed U.S. patent applications encompassing the company's discovery
of two novel molecular targets and their use in the treatment . . .
ENDOVASC INITIATES LIPROSTIN DOSE-RANGING TRIAL FOR
ISCHEMIA.
Endovasc Inc. (OTCBB:EVSC), Montgomery, Texas, early-stage drug
development company that pioneers new cardiovascular and metabolic drug
therapies, has initiated a Phase II dose- ranging trial to . . .
INDEVUS LICENSES WORLDWIDE RIGHTS TO AMINOCANDIN FROM
AVENTIS.
Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV), Lexington, Mass., has
licensed exclusive worldwide rights from Aventis SA (NYSE: AVE) to
aminocandin, a member of a new class of anti-fungal compounds . . .
FDA APPROVES LITHIUM CARBONATE SLOW-RELEASE USP 300MG
TABLETS.
Able Laboratories, Inc. (Nasdaq:ABRX) (BSE:AAB), has received Food
and Drug Administration (FDA) approval for its Abbreviated New Drug
Application (ANDA) for Lithium Carbonate Extended-Release . . .
IMMUSOL'S VIT100 ENTERS PHASE I FOR KELOIDS/HYPERTROPHIC
SCARS.
Immusol, San Diego, Calif. has announced that the first patient was
treated in a Phase I physician-sponsored trial using its investigational
new drug, code named, VIT100, to treat keloids and . . .
TRANSCRIPTION OF ANTISENSE RNA FROM HUMAN GENOME COMMON.
Compugen Ltd. (NASDAQ: CGEN) has announced the discovery that the
transcription of antisense RNAs from the human genome, a phenomenon
usually regarded as very rare, is actually a fairly common . . .
|
|